College of Law > Academics > Centers, Institutes & Initiatives > Mary and Michael Jaharis Health Law Institute > Jaharis Podcast
Pharmacy Deserts Widen Health and Racial Inequities in the USA
April 9, 2022
Featuring Dr. Dima Qato, Hygeia Centennial Chair and Associate Professor of Pharmacy at the University of Southern California School of Pharmacy.
Why are there fewer pharmacies in Black and Hispanic/Latino neighborhoods than White or diverse neighborhoods? Why are Black and Hispanic/Latino neighborhoods more likely to experience pharmacy closures compared with other neighborhoods? How do pharmacy deserts contribute to health and racial disparities in the USA? What are the policies we should implement in the USA to ensure equitable access to pharmacies? I really enjoyed discussing these questions with Dr. Dima Mazen Qato. Dima is Hygeia Centennial Chair and Associate Professor of Pharmacy at the University of Southern California School of Pharmacy. Dima’s work aims to better understand why medications are used, or not used, and how they can and should be used in the population to promote equity, longevity and good health. Dima’s research also utilizes population-based methods to better understand the underlying mechanisms responsible for the use, underuse and unsafe use of medications, how these patterns may influence health outcomes and health disparities, and what can be done from a community and policy perspective to address these growing public health problems. Dima's work on pharmacy deserts has been published in Health Affairs.
Apollo's Arrow: How will COVID-19 affect our society and lives?
January 27, 2022
Featuring Dr. Nicholas Christakis, the Sterling Professor of Social and Natural Science at Yale University.
Stigma, Bias and Discrimination: How Can They Harm Our Health?
Can stigma and discrimination affect our health? What is the rationale behind the blood ban policy and how does it promote stigma and discrimination against healthy gay men? Should the FDA abolish the blood ban policy? I really enjoyed discussing these questions with Doron Dorfman Associate Professor of Law at Syracuse University College of Law. We also thoroughly discussed his latest piece The PrEP Penalty which is forthcoming in Boston College Law Review. The Article uses an innovative experimental study to demonstrate counterintuitive and illogical responses to gay men’s use of PrEP, a highly innovative treatment that significantly reduces HIV infection. Even when participants in the study are educated about the health benefits of the PrEP treatment, on average, they are more reluctant to personally accept blood donated by a gay man who is taking PrEP compared with a gay man not taking PrEP. The findings illustrate how decisions related to public health are colored by moral judgment. As Doron explains, this is detrimental not only to LGBTQ individuals but also to society as a whole.
Gun Violence is a Public Health Crisis
December 13, 2021
Is gun violence pandemic a public health problem? Is there a relationship between gun violence and mental health crisis in the USA? why are poor and segregated neighborhoods disproportionately affected by gun violence in the USA? I really enjoyed discussing these questions with Michael Ulrich, Assistant Professor of Health Law, Ethics, & Human Rights at Boston University’s School of Public Health and School of Law. With Michael we also discussed his latest piece Second Amendment Realism, Forth in Cardozo Law Review which delves into the public health policy implications of the District of Columbia v. Heller case. In this seminal case the Supreme Court said that the Second Amendment protects an individual's right to keep and bear arms, unconnected with service in a militia, for traditionally lawful purposes, such as self-defense within the home. Michael also speaks about his academic path, the challenges he faced throughout his academic journey and the advice he gives students that aspire to pursue a career in the field of health law and public health. Don't miss this fascinating discussion!
Immunity Passports and Contact Tracing Surveillance
Featuring Ignacio N. Cofone, Assistant Professor and Norton Rose Fulbright Faculty Scholar at McGill
Contact tracing apps and immunity passports are being used for the first time in human history. This Article assesses their risk tradeoffs from a private and regulatory law perspective, with special attention to privacy and inequality. The Article begins by developing a surveillance-based taxonomy of contact tracing apps and immunity passports. Next, it demonstrates how these apps magnify the problems and limits of consent and anonymization, two important privacy guarantees. It then explores how the interplay of trust and error can pose threats to health and business efficacy, how they raise issues of liability, and how to address them. It then discusses the prospect that these apps cause discrimination and magnify existing inequalities. Underpinning the aforementioned considerations is a balancing assessment that aims to guide policy-makers, judges, employers, and individuals in making difficult containment decisions.
Am I My Cousin's Keeper? A Proposal to Protect Relatives of Genetic Database Subjects
Featuring Robert I. Field, Professor of Law and of Public Health at Drexel University; Adjunct Senior Fellow at the Leonard Davis Institute of Health Economics at the University of Pennsylvania
Proposing a new regulatory mechanism, “Data Protection Review Boards” (“DPRB”), to balance genetic innovation and Users' privacy. Based on the model of Institutional Review Boards (“IRB”), that oversee the protection of human subjects in research, DPRBs would review data-sharing arrangements between database companies and other private entities with an exclusive focus on privacy risks to data subjects and their identifiable relatives.
Genetic Testing and Predictive Health Analytics
Featuring Sharona Hoffman, Case Western Reserve University
The ever-growing phenomenon of predictive health analytics is generating significant excitement, hope for improved health outcomes, and potential for new revenues. Researchers are developing algorithms to predict suicide, heart disease, stroke, diabetes, cognitive decline, opioid abuse, cancer recurrence, and other ailments.
Integrating Health Innovation Policy
Featuring Rachel Sachs, Washington University
The United States healthcare system is highly fragmented. This fragmentation creates opportunities for multiple actors to make healthcare decisions that would be made better by a single actor, such as when patients receive care from many uncoordinated providers, or when patients move on and off of different insurance plans over time.
Balancing Wealth and Health
Featuring Rochelle Cooper Dreyfuss
A talk about a book that focusses on the debates concerning aspects of intellectual property law that bear on access to medicines in a set of developing countries. Specifically, the contributors look at measures that regulate the acquisition, recognition, and use of patent rights on pharmaceuticals and trade secrets in data concerning them, along with the conditions under which these rights expire so as to permit the production of cheaper generic drugs.
The Cost of Novelty
Featuring Nicholson Price, University of Michigan Law School
Nicholson Price’s paper "The Cost of Novelty" argues that patent law advances new, rather than better. Market value, on which IP law relies, systematically values some goods differently than a social planner or a committee of scientists might.
The Case for Disclosure of Biologics Manufacturing Information
Featuring Yaniv Heled, Georgia State University School of Law
Yaniv Heled’s paper "The Case for Disclosure of Biologics Manufacturing Information" asks whether the law could require disclosure of manufacturing information of biologics. The discussion surrounds public use in data vs public good in incentivizing innovation by keeping information confidential.
Featuring Jessica Roberts, The University of Houston, Director of the Health Law & Policy Institute
Jessica Roberts’s paper "Genetic Duties" discusses genetic Variants of Uncertain Significance (i.e a finding that has been identified through genetic testing, but whose significance to the function or health of an organism is not known), whether patients should be informed about them once their significance is discovered, and whose duty it is to let patients know.
To the Moonshot and Beyond: Cancer and IPFeaturing Jacob Sherkow from New York Law School
Jacob Sherkow from the New York School of Law is our first guest. His recent work focuses on intellectual property and information policy issues surrounding efforts to cure cancer. We discuss patents, the role of public-private partnerships in cancer R&D and the Cancer Moonshot Initiative.
Exploring the MicrobiomeFeaturing Rachel Sachs from Washington University Law
In this episode we explore the microbiome -- the world of microbes inside your body. Rachel Sachs from the Washington University School of Law in Saint Louis joins us to discuss intellectual property issues surrounding the microbiome, including emerging treatments and therapies that are starting to take advantage of microbiome research.
Fighting Antibiotic ResistanceFeaturing Kevin Outterson, Executive Director of CARB-X
More than 23,000 people die every year in the US from antibiotic-resistant bacteria. We welcome to the podcast Kevin Outterson, executive director of CARB-X (Combating Antibiotic Resistance Bacteria Biopharmaceutical Accelerator), a USD 450 million partnership that is taking the lead in protecting humanity from bacterial threats.
Federally Funded Research: Approaching Four Decades of the Bayh-Dole ActFeaturing Lisa Ouellete, Associate Professor at Stanford Law School
In 1980, Congress enacted the Bayh-Dole Act, which is often considered the "basis of the biotech revolution." In this episode, we explore the impact of patents on federally funded research at universities and other institutions in the wake of Bayh-Dole with Lisa Ouellete, who has written extensively on the topic.
Medicine of the Future: From Biologics to Black Box MedicineFeaturing Nicholson Price, Assistant Professor of Law at University of Michigan Law School
Biologics are often hailed as the most promising drugs currently available to patients. However, they are extraordinarily difficult to replicate, a feature that poses unique problems to competitors and regulators. Today we talk with Nicholson Price about this issue and about “black box” medicine: what happens when we rely on algorithms for diagnostics or to identify therapies?
Investor-State Arbitration and “Alternative Facts” in Pharmaceutical MarketingFeaturing Cynthia Ho, Clifford E. Vickrey Research Professor and Director, Intellectual Property Program at Loyola University Chicago School of Law
Cynthia Ho provides an overview of two different fields with implications for public health. We start by discussing international agreements that allow foreign companies to bring claims against states on the grounds that their investments—including those in the form of intellectual property, such as pharmaceutical patents—have been compromised. We then talk about Cynthia’s latest article, in which she argues that, in some situations, pharmaceutical marketing to doctors may be considered “alternative facts” and therefore entitled to less First Amendment protection.